<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337660</url>
  </required_header>
  <id_info>
    <org_study_id>SIRG-1</org_study_id>
    <nct_id>NCT02337660</nct_id>
  </id_info>
  <brief_title>Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia</brief_title>
  <official_title>Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Novo Nordisk Foundation Center for Basic Metabolic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether non-alcoholic fatty liver disease (NAFLD) is
      associated with hepatic glucagon resistance and hyperglucagonemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperglucagonemia is a common condition in obesity, prediabetes and type 2 diabetes. It
      increases the hepatic glucose production, thus contributing to type 2-diabetic hyperglycemia.
      In the current study we wish to examine whether non-alcoholic fatty disease (NAFLD) results
      in hepatic glucagon resistance. This could result in hyperglucagonemia through a feedback
      mechanism acting on the level of pancreatic alpha cells. Cirrhosis and type 1 diabetes,
      respectively, has previously been shown to be associated with hepatic glucagon resistance but
      it has not been examined in relation to NAFLD in humans so far.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urea synthesis</measure>
    <time_frame>up to 180 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>From time 0 to 180min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma glucose level</measure>
    <time_frame>time 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of steatosis</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Healthy, lean</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 healthy, lean subjects.
Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, otherwise healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 obese, otherwise healthy subjects
Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>One ultrasound guided liver biopsy</description>
    <arm_group_label>Healthy, lean</arm_group_label>
    <arm_group_label>Obese, otherwise healthy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pancreatic clamp</intervention_name>
    <description>I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.</description>
    <arm_group_label>Healthy, lean</arm_group_label>
    <arm_group_label>Obese, otherwise healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal fasting plasma glucose and HbA1c &lt; 6.0%

          -  Between 18.5 and 25 kg/m2 or between 30 and 40 kg/m2

          -  Normal haemoglobin

          -  Normal coagulation factor II, VII and X, INR and thrombocytes

          -  Age above 25 years

          -  Informed consent

        Exclusion Criteria:

          -  Diabetes

          -  Prediabetes (impaired glucose tolerance and/or impaired fasting plasma glucose)

          -  First-degree relatives with diabetes

          -  Nephropathy (eGFR &lt; 60ml/min and/or albuminuria)

          -  Liver disease (ALAT and/or serum ASAT &gt;2x normal values)

          -  Use of anticoagulative medicine like Clopidogrel og Warfarin

          -  Pregnancy and/or breastfeeding

          -  Age above 80 years

          -  Any condition that the investigator feels would interfere with trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Diabetes Research</name>
      <address>
        <city>Gentofte</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990 Nov;39(11):1381-90.</citation>
    <PMID>2121568</PMID>
  </reference>
  <reference>
    <citation>Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007 Feb;28(1):84-116. Epub 2007 Jan 16. Review.</citation>
    <PMID>17261637</PMID>
  </reference>
  <reference>
    <citation>Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T, Madsbad S. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab. 2012 Jun;14(6):500-10. doi: 10.1111/j.1463-1326.2011.01549.x. Epub 2012 Jan 17.</citation>
    <PMID>22171657</PMID>
  </reference>
  <reference>
    <citation>Færch K, Pilgaard K, Knop FK, Hansen T, Pedersen O, Jørgensen T, Holst JJ. Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes Obes Metab. 2013 Jan;15(1):91-5. doi: 10.1111/j.1463-1326.2012.01675.x. Epub 2012 Sep 9.</citation>
    <PMID>22862926</PMID>
  </reference>
  <reference>
    <citation>Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992 Jan 2;326(1):22-9.</citation>
    <PMID>1727062</PMID>
  </reference>
  <reference>
    <citation>Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975 Jan 4;1(7897):14-6.</citation>
    <PMID>46337</PMID>
  </reference>
  <reference>
    <citation>Liljenquist JE, Mueller GL, Cherrington AD, Keller U, Chiasson J-L, Perry JM, Lacy WW, Rabinowitz D. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest. 1977 Feb;59(2):369-74.</citation>
    <PMID>833282</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Muscelli E, Natali A, Gabriel R, Mitrakou A, Flyvbjerg A, Golay A, Hojlund K; Relationship between Insulin Sensitivity and Cardiovascular Disease Risk (RISC) Project Investigators. Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia. 2007 Nov;50(11):2342-7. Epub 2007 Sep 11.</citation>
    <PMID>17846745</PMID>
  </reference>
  <reference>
    <citation>Charbonneau A, Couturier K, Gauthier MS, Lavoie JM. Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. Int J Sports Med. 2005 Jul-Aug;26(6):432-41.</citation>
    <PMID>16037884</PMID>
  </reference>
  <reference>
    <citation>Longuet C, Robledo AM, Dean ED, Dai C, Ali S, McGuinness I, de Chavez V, Vuguin PM, Charron MJ, Powers AC, Drucker DJ. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes. 2013 Apr;62(4):1196-205. doi: 10.2337/db11-1605. Epub 2012 Nov 16.</citation>
    <PMID>23160527</PMID>
  </reference>
  <reference>
    <citation>Bhathena SJ, Voyles NR, Smith S, Recant L. Decreased glucagon receptors in diabetic rat hepatocytes. Evidence for regulation of glucagon receptors by hyperglucagonemia. J Clin Invest. 1978 Jun;61(6):1488-97.</citation>
    <PMID>207737</PMID>
  </reference>
  <reference>
    <citation>Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993 Nov;42(11):1663-72.</citation>
    <PMID>8405710</PMID>
  </reference>
  <reference>
    <citation>Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005 Sep;22(9):1141-5.</citation>
    <PMID>16108839</PMID>
  </reference>
  <reference>
    <citation>Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004 Aug;19(8):854-8.</citation>
    <PMID>15242486</PMID>
  </reference>
  <reference>
    <citation>Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care. 2003 Dec;26(12):3351-2.</citation>
    <PMID>14633828</PMID>
  </reference>
  <reference>
    <citation>Seghieri M, Rebelos E, Gastaldelli A, Astiarraga BD, Casolaro A, Barsotti E, Pocai A, Nauck M, Muscelli E, Ferrannini E. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. 2013 Jan;56(1):156-61. doi: 10.1007/s00125-012-2738-3. Epub 2012 Oct 12.</citation>
    <PMID>23064290</PMID>
  </reference>
  <reference>
    <citation>Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010 Jul;59(7):1765-70. doi: 10.2337/db09-1414. Epub 2010 Feb 11.</citation>
    <PMID>20150286</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>June 4, 2016</last_update_submitted>
  <last_update_submitted_qc>June 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Malte Palm Suppli</investigator_full_name>
    <investigator_title>Research year assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

